Expression of drug resistance-related genes in head and neck squamous cell carcinoma and normal mucosa

Japanese Journal of Cancer Research

Volumn 91, Issue 1, 2000, Pages 84-90

  Hirata, Shitau ^a   Katoh, Osamu ^b   Oguri, Tetsuya ^a   Watanabe, Hiromitsu ^b   Yajin, Koji ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

DNA topoisomerase II; Drug resistance related gene; Head and neck squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PLATINUM DERIVATIVE;

ADULT; AGED; ANION TRANSPORT; ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MUCOSA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

EID: 0034011920     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00863.x     Document Type: Article

References (47)

1. Chen, C., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M. and Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1(P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-389 (1986).
2. Gottesman, M. M. and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
3. Germann, U. A. P-Glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer, 32A, 927-944 (1996).
4. Loe, D. W., Deeley, R. G. and Cole, S. P. C. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer, 32A, 945-957 (1996).
5. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S. and Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressied in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56, 4124-4129 (1996).
6. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Schroeijers, A. B., van der Valk, P. and Scheper, R. J. Major vault protein LRP-related multidrug resistance. Eur. J. Cancer, 32A, 979-984 (1996).
7. Zhou, D. C., Zittoun, R. and Marie, J. P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia, 9, 1661-1666 (1995).
8. Hasegawa, S., Abe, T., Naito, S., Kotoh, S., Kumazawa, J., Hipfner, D. R., Cole, S. P. C. and Kuwano, M. Expression of multidrug resistance-associated protein (MRP), MDR1, and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer, 71, 907-913 (1995).
9. Fairchild, C. R., Ivy, S. P., Rushmore, T., Lee, G., Koo, P., Goldsmith, M. E., Myers, C. E., Farber, E. and Cowan, K. H. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 84, 7701-7705 (1987).
10. Nitiss, J. L. and Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer, 32A, 958-966 (1996).
11. Wang, J. C. DNA topoisomerases: why so many? J. Biol. Chem., 266, 6659-6662 (1991).
12. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T. and Mirabelli, C. K. Biochemical and pharmacological properties of p 170 and p 180 forms of topoisomerase II. Biochemistry, 28, 8154-8160 (1989).
13. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K. and Drake, F. H. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2, 209-214 (1991).
14. Meyer, K. N., Kjeldsen, E., Straub, T., Knudsen, B. R., Hickson, I. D., Kikuchi, A., Kreipe, H. and Boege, F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J. Cell Biol., 136, 775-788 (1997).
15. Chen, A. Y. and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34, 191-218 (1994).
16. Cornarotti, M. Capranico, G., Bohm, S., Oriana, S., Spatti, G. B., Mariani, L., Ballabio, G. and Zunino, F. Gene expression of DNA topoisomerases I. IIα and IIβ and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int. J. Cancer. 67, 479-484 (1996).
17. Giaccone, G., van Ark-Otte, J., Scagliotti, G., Capranico, G., van der Valk, P., Rubio, G., Dalesio, O., Lopez, R., Zunio, F., Walboomers, J. and Pinedo, H. M. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim. Biophys. Acta. 1264, 337-346 (1995).
18. Syahruddin, E., Oguri, T., Takahashi, T., Isobe, T., Fujiwara, Y. and Yamakido, M. Differential expression of DNA topoisomerase IIα and IIβ genes between small cell and non-small cell lung cancer. Jpn. J. Cancer Res., 89, 855-861 (1998).
19. Ohashi, N., Fujiwara, Y., Yamaoka, N., Katoh, O., Satow, Y. and Yamakido, M. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn. J. Cancer Res., 87, 1280-1287 (1996).
20. Giaccone, G., Gazdar, A. F., Beck, H., Zunino, F. and Capranico, G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res., 52, 1666-1674 (1992).
21. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase 1-targeted chemotherapy of human colon career in xenografts. Science, 246, 1046-1048 (1989).
22. Bader, P., Fuchs, J., Wenderoth, M., von Schweinitz., D., Niethammer, D. and Beck, J. F. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamicin or cisplatin. Anticancer Res., 18, 3127-3132 (1998).
23. Koike, K., Abe, T., Hisano, T., Kubo, T., Wada, M., Kohno, K. and Kuwano, M. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Jpn. J. Cancer Res., 87, 765-772 (1996).
24. Oguri, T., Fujiwara, Y., Isobe, T., Katoh, O., Watanabe, H. and Yamakido, M. Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancer to platinum drugs. Br. J. Cancer, 77, 1089-1096 (1998).
25. Abe, Y., Nakamura, M., Ota, E., Ozeki, Y., Tamai, S., Inoue, H., Ueyama, Y., Ogata, T. and Tamaoki, N. Expression of the multidrug resistance gene (MDRI] in non-small cell lung cancer. Jpn. J. Cancer Res., 85, 536-541 (1994).
26. Kreisholt, J., Sorensen, M., Jensen, P. B., Nielsen, B. S., Anderson, C. B. and Sehested, M. Immunohistochemical detection of DNA topoisomerase IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br. J. Cancer, 77, 1469-1473 (1998).
27. Oguri, T., Fujiwara, Y., Ochiai, M., Fujitaka, K., Miyazaki, M., Takahashi, T., Yokozaki, M., Isobe, T., Ohune, T., Tsuya, T., Katoh, O. and Yamakido, M. Expression of lung-resistance protein gene is not associated with platinum drug exposure in lung cancer. Anticancer Res., 18, 4159-4162 (1998).
28. Kim, W. J., Kakehi, Y., Kinoshita, H., Arao, S., Fukumoto. M. and Yoshida, O. Expression patterns of multidrug-resistance (MDR1). multidrug resistance-associated protein (MRP), glutathione S-transferase-π (GST-π) and topoisomerase II (TopoII) genes in renal cell carcinomas and normal kidney. J. Urol., 156, 506-511 (1996).
29. Kakehi, Y., Wu, W.-J., Kim, W.-J., Arao, S., Fukumoto, M. and Yoshida, O. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. Int. J. Urol., 2, 309-315 (1995).
30. Sandri, M. I., Hochhauser, D., Ayton, P., Camplejohn, R. C., Whitehouse, R., Turley, H., Gatter, K., Hickson, I. D. and Harris, A. L. Differential expression of the topoisomerase IIα and β genes in human breast cancers. Br. J. Cancer, 73, 1518-1524 (1996).
31. Schneider, J., Rubio, M. P., Barbazan, M.J., Rodriguez, E. F. J., Seizinger, B. R. and Castresana, J. S. P-Glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl. Cancer Inst., 86, 850-858 (1994).
32. Izquierdo, M. A., van der Zee, A. G. J., Vermorken, J. B., van der Valk, P., Beliën, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., Meijer, C. J. L. M., de Vries, E. G. E. and Scheper, R. J. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87, 1230-1237 (1995).
33. van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G. and de Vries, E. G. E. P-Glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/ cyclophosphamide chemotherapy. Cancer Res., 51, 5915-5920 (1991).
34. Ito, K., Fujimori, M., Kohno, K., Nakagawa, A., Kuwano, M. and Amano, J. Expression of multidrug resistance associated genes in paired cases of breast cancers and adjacent normal breast tissues. Proc. Am. Assoc. Cancer Res., 38, 388 (1997).
35. Yamazaki, K., Isobe, H., Hanada, T., Betsuyaku, T., Hasegawa, A, Hizawa, N., Ogura, S. and Kawakami, Y. Topoisomerase IIα content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol., 39, 192-198 (1997).
36. Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J. R., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R., Boersma, T., Sonneveld, P., Gratama, J. W., Kok, T., Eggermont, A. M. M., Bosman, F. T. and Stoter, G. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res., 1, 1301-1310 (1995).
37. Schadendorf, D., Makki, A., Stahr, C., van Dyck, A., Wanner, R., Scheffer, G. L., Flens, M. J., Scheper, R. and Henz, B. M. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am. J. Pathol., 147, 1545-1552 (1995).
38. Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Giaccone, G., Broxterman, H. J., Meijer, C. J. L. M., van der Valk, P. and Scheper, R. J. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol., 148, 877-887 (1996).
39. Kelley, D. J., Pavelic, Z. P., Gapany, M., Stambrook, P., Pavelic, L., Gapany, S. and Gluckman, J. L. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch. Otolaryngol. Head Neck Surg., 119, 411-414 (1993).
40. Tsuzuki, H., Saito, H., Ohtsubo, T., Tanaka, N., Noda, I., Sugimoto, C., Tsuda, G. and Imamura, Y. Immunohistochemical detection of P-glycoprotein and chemosensitivity from ATP assay in human head and neck malignant tumor. Head Neck Cancer, 22, 1-6 (1996).
41. Welters, M. J. P., Fichtinger-Schepman, A. M. J., Baan, R. A., Flens, M. J., Scheper, R. J. and Braakhuis, B. J. M. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br. J. Cancer, 77, 556-561 (1998).
42. Saito, H., Tanaka, N., Sugimoto, C. and Tsuzuki, H. Anticancer drug resistance and approaches to overcoming it in head and neck cancer. Pract. Otol. (Kyoto), 90, 607-614 (1997).
43. Duensing, S., Dallmann, I., Grosse, J., Buer, J., Hänninen, E. L., Deckert, M., Störkel, S., Kirchner, H., Poliwoda, H. and Atzpodien, J. Immunohistochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology, 51, 309 (1994).
44. Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R. and Scheper, R. J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer, 65, 230-237 (1996).
45. Ishikawa, T., Bao, J. J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D. and Kuo, M. T. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem., 271, 14981-14988 (1996).
46. Horikoshi, T., Danenberg, K. D., Stadibauer, T. H. W., Volkenandt, M., Shea, L. C. C., Aigner, K., Gustavsson, B., Leichman, L., Frosing, R., Ray, M., Gibson, N. W., Spears, C. P. and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52, 108-116 (1992).
47. Ishikawa, Y., Kubota, T., Otani, Y., Watanabe, M., Teramato, T., Kumai, K., Kitajima, M., Takechi, T., Okabe, H. and Fukushima, M. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the anticancer effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin. Cancer Res., 5, 883-889 (1999).